(CHEMM) ChemoMetec - Ratings and Ratios
Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0060055861
CHEMM: Analytical Equipment, Cell Counters, Consumables, Accessories, Services
ChemoMetec A/S is a Denmark-based company specializing in the development, production, and distribution of advanced analytical instruments for cell counting and analysis. Established in 1997 and headquartered in Allerød, the firm serves a global clientele across the United States, Canada, Europe, and international markets. Its solutions cater to diverse sectors, including cell and gene therapy, cancer and stem cell research, pharmaceutical development and manufacturing, as well as quality control in animal semen, milk, and beer production. The companys product portfolio includes the NucleoCounter series, such as the NC-3000, NC-250, NC-202, and NC-200, which provide precise cell counting and viability determination. Additionally, it offers the SP-100 for automated sperm cell counting and the XcytoMatic 40 for cell density and viability analysis. ChemoMetec also provides consumables like cassettes, reagents, and slides, along with accessories and services such as validation plans, training, and software support. The company is currently developing the XcytoMatic 30 cell counter to further expand its product range.
ChemoMetec A/S operates in the life sciences tools and services sector, with a strong focus on innovation and precision in cell analysis. Its products are integral to research, development, and quality control processes across pharmaceuticals, biotechnology, and animal health industries. The companys commitment to advancing cell counting technology has established it as a key player in its niche market.
Based on the provided technical and fundamental data, here is a 3-month forecast for ChemoMetec A/S (CO:CHEMM):
Over the next three months, ChemoMetec A/S is expected to maintain its upward momentum, supported by its strong financials and growing demand for cell analysis solutions. The stock may face resistance near the 50-day SMA (529.01) but could break out above this level if demand strengthens. Support is likely to hold near the 200-day SMA (458.04). Investors should monitor volume and volatility, as the ATR suggests potential price swings. The companys high P/E ratio may attract profit-taking, but its robust RoE and revenue growth could sustain upward pressure.
Additional Sources for CHEMM Stock
CHEMM Stock Overview
| Market Cap in USD | 1,269m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2006-12-18 |
CHEMM Stock Ratings
| Growth Rating | 21.5 |
| Fundamental | 63.3 |
| Dividend Rating | 6.52 |
| Rel. Strength | 67.7 |
| Analysts | - |
| Fair Price Momentum | 456.09 DKK |
| Fair Price DCF | 81.29 DKK |
CHEMM Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 22.1% |
CHEMM Growth Ratios
| Growth Correlation 3m | -60% |
| Growth Correlation 12m | 89.5% |
| Growth Correlation 5y | -27.8% |
| CAGR 5y | 7.88% |
| CAGR/Max DD 5y | 0.10 |
| Sharpe Ratio 12m | -0.54 |
| Alpha | 51.25 |
| Beta | 1.307 |
| Volatility | 53.18% |
| Current Volume | 47.6k |
| Average Volume 20d | 34.6k |
As of April 25, 2025, the stock is trading at DKK 473.00 with a total of 47,605 shares traded.
Over the past week, the price has changed by -1.00%, over one month by -9.90%, over three months by -4.98% and over the past year by +66.20%.
Yes, based on ValueRay Fundamental Analyses, ChemoMetec (CO:CHEMM) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 63.28 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CHEMM as of April 2025 is 456.09. This means that CHEMM is currently overvalued and has a potential downside of -3.58%.
ChemoMetec has no consensus analysts rating.
According to ValueRays Forecast Model, CHEMM ChemoMetec will be worth about 520.8 in April 2026. The stock is currently trading at 473.00. This means that the stock has a potential upside of +10.11%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 652.5 | 37.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 520.8 | 10.1% |